

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VISEN Pharmaceuticals
维昇药业

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2561)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of VISEN Pharmaceuticals (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Thursday, 12 March 2026 for the purpose of, among other matters, considering and approving the annual results of the Group for the year ended 31 December 2025 and its publication, and transacting any other business.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, 2 March 2026

As at the date of this notice, the Board comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.